Search Results - alan+bermingham

2 Results Sort By:
Tumor-pH–Triggered Doxorubicin Prodrug with On-Demand Shelf-Stable Precursor
This invention introduces a small-molecule doxorubicin prodrug that remains inert in blood and rapidly activates in the mildly acidic tumor microenvironment. Featuring a shelf-stable maleimide pre-prodrug that converts on demand to the ultra-acid-labile DMA form, it enables targeted chemotherapy with improved selectivity, scalable synthesis, and reduced...
Published: 10/10/2025   |   Inventor(s): Ming An, Lan Yao, Vladyslav Nazarenko
Keywords(s): Technologies
Category(s): Campus > Binghamton University
Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues
Abstract: Topoisomerase enzymes play an important role in cancer progression by controlling changes in DNA structure through catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle. Therefore, topoisomerases are important targets for cancer chemotherapy. Many topoisomerase 1 (TOP1) inhibitors...
Published: 4/22/2025   |   Inventor(s): Barry O'Keefe, Lauren Krumpe, Johan Rosengren, Ingrid Schroeder, Alan Bermingham, Christophe Marchand, Kirk Gustafson, Brice Wilson, Yves Pommier
Keywords(s): CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics